Table 1—

Patient demographic characteristics at screening (week −4)

EXUSC insulin
n290290
Men/women (%)169/121 (58/42)161/129 (56/44)
Race (%)
    White254 (87.6)261 (90)
    Black11 (3.8)5 (1.7)
    Asian1 (0.3)3 (1.0)
    Hispanic19 (6.6)18 (6.2)
    Other5 (1.7)3 (1.0)
Age (years)37.6 ± 11.036.5 ± 11.6
Weight (kg)74.8 ± 13.673.5 ± 13.3
Height (cm)172.3 ± 9.7171.2 ± 10.3
BMI (kg/m2)25.1 ± 3.025.0 ± 3.1
A1C (%)7.8 ± 1.27.9 ± 1.2
C-peptide (pmol/ml)0.15 ± 0.050.15 ± 0.05
Duration of diabetes (years)18.4 (1.0–51.8)17.4 (1.0–48.7)
FEV1*
    Observed (l)3.50 ± 0.763.47 ± 0.77
    Predicted (%)93.1 ± 10.893.2 ± 10.5
DLCO*
    Observed (ml · min−1 · mmHg−1)28.09 ± 6.2227.20 ± 6.41
    Predicted (%)94.7 ± 13.292.2 ± 12.6
  • Data are means ± SD (range) unless otherwise indicated.

  • *

    * FEV1 and DLCO test values at study entry were defined as the means of the values obtained before the first dose of study drug after randomization.